GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (OTCPK:TLTFF) » Definitions » 3-Year FCF Growth Rate

Theralase Technologies (Theralase Technologies) 3-Year FCF Growth Rate : 6.20% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Theralase Technologies 3-Year FCF Growth Rate?

Theralase Technologies's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 6.20% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -3.10% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Theralase Technologies was 43.30% per year. The lowest was -104.10% per year. And the median was -7.00% per year.


Competitive Comparison of Theralase Technologies's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Theralase Technologies's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's 3-Year FCF Growth Rate falls into.



Theralase Technologies 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Theralase Technologies  (OTCPK:TLTFF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Theralase Technologies 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies (Theralase Technologies) Business Description

Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.